Plus Therapeutics (NASDAQ:PSTV) Announces Quarterly Earnings Results

Plus Therapeutics (NASDAQ:PSTV) posted its earnings results on Thursday. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.43), FiscalAI reports. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.11 million.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV traded down $0.02 during mid-day trading on Friday, reaching $3.68. 109,031 shares of the company traded hands, compared to its average volume of 116,506. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The firm has a market cap of $25.33 million, a PE ratio of -1.60 and a beta of 1.40. The stock has a fifty day simple moving average of $4.12 and a 200-day simple moving average of $5.44.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PSTV. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Ascendiant Capital Markets reduced their price target on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Plus Therapeutics presently has an average rating of “Hold” and an average target price of $56.40.

Hedge Funds Weigh In On Plus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics in the 2nd quarter worth $41,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the third quarter valued at about $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter worth about $100,000. XTX Topco Ltd acquired a new position in Plus Therapeutics during the fourth quarter worth about $127,000. Finally, State Street Corp raised its position in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares in the last quarter. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.